摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-iodo-1-β-D-ribofuranosylpyrazole-3-carboxamide | 138787-01-6

中文名称
——
中文别名
——
英文名称
4-iodo-1-β-D-ribofuranosylpyrazole-3-carboxamide
英文别名
1-beta-D-Ribofuranosyl-4-iodopyrazole-3-carboxamide;1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-iodopyrazole-3-carboxamide
4-iodo-1-β-D-ribofuranosylpyrazole-3-carboxamide化学式
CAS
138787-01-6
化学式
C9H12IN3O5
mdl
——
分子量
369.116
InChiKey
QONCHRHGFNMWIN-FJGDRVTGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    567.5±50.0 °C(Predicted)
  • 密度:
    2.24±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    131
  • 氢给体数:
    4
  • 氢受体数:
    6

SDS

SDS:e4e251189d7df92e6fe7342799149754
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-iodo-1-β-D-ribofuranosylpyrazole-3-carboxamide 在 Proton Sponge 、 三氯氧磷三正丁胺三丁基焦磷酸铵 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以27%的产率得到4-iodo-1-β-D-ribofuranosylpyrazole-3-carboxamide 5'-triphosphate
    参考文献:
    名称:
    Effects of Introduction of Hydrophobic Group on Ribavirin Base on Mutation Induction and Anti-RNA Viral Activity
    摘要:
    One of the possible mechanisms of antiviral action of ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, 1) is the accumulation of mutations in viral genomic RNA. The ambiguous incorporation of 5'-triphosphate of ribavirin (RTP, 8) by a viral RNA-dependent RNA polymerase (RdRp) is a key step of the mutation induction. We synthesized three ribavirin analogues that possess hydrophobic groups, 4-iodo-1- 1-beta-D-ribofuranosylpyrazole-3-carboxamide (7a), 4-propynyl-1-beta-D-ribofuranosylpyrazole-3-carboxamide (7b), and 4-phenylethynyl-1-beta-D-ribofuranosylpyrazole-3-carboxamide (7c), and the corresponding triphosphates (9a, 9b, and 9c, respectively). Steady-state kinetics analysis of the incorporation of these triphosphate analogues by a poliovirus RdRp, 3D(pol), revealed that while the incorporation efficiency of 9a was comparable to RTP, 9b and 9c showed lower efficiency than RTP. Antipolioviral activity of 7a and 7b was much more moderate than ribavirin, and 7c showed no antipolioviral activity. Effects of substituting groups on the incorporation efficiency by 3D(pol) and a strategy for a rational design of more active ribavirin analogues are discussed.
    DOI:
    10.1021/jm7009952
  • 作为产物:
    参考文献:
    名称:
    吡唑相关的核苷。某些取代的吡唑和吡唑并[4,3-d] -1,2,3-三嗪-4-酮核苷的合成及抗病毒/抗肿瘤活性。
    摘要:
    制备了几种吡唑和吡唑并[4,3-d] -1,2,3-三嗪-4-一核糖核苷,并测试了其抗病毒/抗肿瘤活性。通过标准方法制备适当的杂环碱。吡唑6a-e,g,i和吡唑并[4,3-d] -1,2,3-三嗪-4-酮12f-1的糖基化反应,是通过六甲基二硅氮烷与1-β-O-乙酰基-甲硅烷基化作用介导的2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖的相应糖苷7a-e,g,8g,i,13f,h,k和14f的收率很高,但不能应用于化合物12g ,i,j,l。为了克服这种情况,需要一种不同的策略,涉及适当的吡唑糖苷9和10的制备,重氮化和原位环化。此外,具有通式5的衍生物不仅被认为是3的合成中的合成中间体,而且还被认为是利巴韦林4的碳生物等排体。在体外对所有化合物进行了细胞抑制和抗病毒活性的评价。所产生的吡唑并[4,3-d] -1,2,3-三嗪-4-酮核苷基本上没有任何活性。仅15h,k显示出对T细胞的中等细胞
    DOI:
    10.1021/jm00083a017
点击查看最新优质反应信息

文献信息

  • Effects of Introduction of Hydrophobic Group on Ribavirin Base on Mutation Induction and Anti-RNA Viral Activity
    作者:Kei Moriyama、Tetsuya Suzuki、Kazuo Negishi、Jason D. Graci、Corinne N. Thompson、Craig E. Cameron、Masahiko Watanabe
    DOI:10.1021/jm7009952
    日期:2008.1.1
    One of the possible mechanisms of antiviral action of ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, 1) is the accumulation of mutations in viral genomic RNA. The ambiguous incorporation of 5'-triphosphate of ribavirin (RTP, 8) by a viral RNA-dependent RNA polymerase (RdRp) is a key step of the mutation induction. We synthesized three ribavirin analogues that possess hydrophobic groups, 4-iodo-1- 1-beta-D-ribofuranosylpyrazole-3-carboxamide (7a), 4-propynyl-1-beta-D-ribofuranosylpyrazole-3-carboxamide (7b), and 4-phenylethynyl-1-beta-D-ribofuranosylpyrazole-3-carboxamide (7c), and the corresponding triphosphates (9a, 9b, and 9c, respectively). Steady-state kinetics analysis of the incorporation of these triphosphate analogues by a poliovirus RdRp, 3D(pol), revealed that while the incorporation efficiency of 9a was comparable to RTP, 9b and 9c showed lower efficiency than RTP. Antipolioviral activity of 7a and 7b was much more moderate than ribavirin, and 7c showed no antipolioviral activity. Effects of substituting groups on the incorporation efficiency by 3D(pol) and a strategy for a rational design of more active ribavirin analogues are discussed.
  • Pyrazole-related nucleosides. Synthesis and antiviral/antitumor activity of some substituted pyrazole and pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides
    作者:Stefano Manfredini、Rita Bazzanini、Pier Giovanni Baraldi、Mario Guarneri、Daniele Simoni、Maria E. Marongiu、Alessandra Pani、Paolo La Colla、Enzo Tramontano
    DOI:10.1021/jm00083a017
    日期:1992.3
    preparation, diazotization, and in situ cyclization of opportune pyrazole glycosides 9 and 10 was required. Moreover derivatives having the general formula 5 were considered not only as synthetic intermediates in the synthesis of 3 but also as carbon bioisosteres of ribavirin 4. All compounds were evaluated in vitro for cytostatic and antiviral activity. The pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides that
    制备了几种吡唑和吡唑并[4,3-d] -1,2,3-三嗪-4-一核糖核苷,并测试了其抗病毒/抗肿瘤活性。通过标准方法制备适当的杂环碱。吡唑6a-e,g,i和吡唑并[4,3-d] -1,2,3-三嗪-4-酮12f-1的糖基化反应,是通过六甲基二硅氮烷与1-β-O-乙酰基-甲硅烷基化作用介导的2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖的相应糖苷7a-e,g,8g,i,13f,h,k和14f的收率很高,但不能应用于化合物12g ,i,j,l。为了克服这种情况,需要一种不同的策略,涉及适当的吡唑糖苷9和10的制备,重氮化和原位环化。此外,具有通式5的衍生物不仅被认为是3的合成中的合成中间体,而且还被认为是利巴韦林4的碳生物等排体。在体外对所有化合物进行了细胞抑制和抗病毒活性的评价。所产生的吡唑并[4,3-d] -1,2,3-三嗪-4-酮核苷基本上没有任何活性。仅15h,k显示出对T细胞的中等细胞
查看更多

同类化合物

5-甲基-4-硝基-1-(β-D-呋喃核糖基)-1H-吡唑-3-甲酰胺 1-[(2R,3R,4S,5R)-3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]吡唑-3,4-二甲酰胺 1-β-D-ribofuranosylpyrazole 4-iodo-3-(3'-methyl-1',2',4'-oxadiazolyl)-1-β-D-ribofuranosylpyrazole 5-amino-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)pyrazole-4-carboxamide 3,5-dimethyl-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)pyrazole 4-phenylethynyl-1-β-D-ribofuranosylpyrazole-3-carboxamide 3,5-dimethyl-1-(α-D-arabinofuranosyl)pyrazole methyl 5-amino-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)pyrazole-4-carboxylate ethyl 1-(2,3-O-isopropylidene-β-D-ribofuranosyl)-5-<(N'-ethoxycarbonylthiocarbamoyl)amino>pyrazole-4-carboxylate methyl 3-[5-amino-1-(2,3-O-isopropylidene-β-D-ribofuranosyl)-1H-pirazol-4-yl]-4,4,4-trifluoro-3-hydroxybutanoate 5-Amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazole-4-carboximidamide 1-[3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-(dimethylaminodiazenyl)pyrazole-4-carboxamide 3-Amino-1-pentofuranosyl-1h-pyrazole-4-carboxamide 5-Amino-1-pentofuranosyl-1h-pyrazole-4-carboxamide 1-(β-D-ribofuranosyl)pyrazole-4-carboxamide 1-(β-D-ribofuranosyl)pyrazole-4-thiocarboxamide 5-bromo-1-(β-D-ribofuranosyl)pyrazole-4-carboxamide 5-bromo-1-(β-D-ribofuranosyl)pyrazole-4-carboxamidoxime 5-amino-1-(β-D-ribofuranosyl)pyrazole-4-carboxamidoxime 1-(β-D-ribofuranosyl)pyrazole-4-carbonitrile 5-bromo-1-(β-D-ribofuranosyl)pyrazole-4-carbonitrile 5-bromo-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)pyrazole-4-carbonitrile 5-amino-1-(β-D-ribofuranosyl)pyrazole-4-carbonitrile 1-(β-D-ribofuranosyl)pyrazole-4-carboxamidoxime 2-[3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazole-3-carboxamide 1H-Pyrazole-3-carboxamide, 1-beta-D-ribofuranosyl- 1H-Pyrazolo-3-carboxamide, 4-amino-1-beta-D-ribofuranosyl- 1H-Pyrazole-5-carboxamide, 4-amino-1-beta-D-ribofuranosyl- 1-[3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazole-3,5-dicarboxamide 2-[5-amino-4-(1H-1,2,4-triazol-5-yl)pyrazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol Ethyl 2-[3,4-diacetyloxy-5-(acetyloxymethyl)oxolan-2-yl]-4-nitropyrazole-3-carboxylate 1-(2,3-O-isopropylidene-β-D-ribofuranosyl)-3-methyl-5-(methylthio)pyrazole methyl 4-phenylethynyl-1-(2',3',5'-tribenzoyl-β-D-ribofuranosyl)pyrazole-3-carboxylate 3,5-dimethyl-1-(2,3,5-tri-O-benzyl-β-D-arabinofuranosyl)pyrazole methyl 4-propynyl-1-(2',3',5'-tribenzoyl-β-D-ribofuranosyl)pyrazole-3-carboxylate 5-amino-1-(2',3'O-isopropylidene-β-D-ribofuranosyl)pyrazole-4-carboxamide 1-(2,3-O-isopropylidene-β-D-ribofuranosyl)-5-<(N'-benzoyl-S-methylisothiocarbamoyl)amino>pyrazole-4-carboxamide 5-amino-1-(β-D-ribofuranosyl)pyrazole-4-carboxamide methyl 4-iodo-1-β-D-ribofuranosyl-pyrazole-3-carboxylate 5-amino-1-(2,3-O-isopropylidene-β-D-ribofuranosyl)pyrazole-4-carboxaldehyde 1-deoxy-1-N-pyrazolyl-2,3-O-isopropylidene-D-ribofuranose 1-(3,5-dimethyl-pyrazol-1-yl)-O2,O3-isopropylidene-D-1,4-anhydro-ribitol methyl 3-cyanomethyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)pyrazole-4-carboxylate 3-cyanomethyl-1-β-D-ribofuranosylpyrazole-4-carboxamide methyl 3-cyanomethyl-1-β-D-ribofuranosylpyrazole-4-carboxylate 1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-5-(chloromethyl)pyrazole-3-carboxamide 1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-3-(chloromethyl)pyrazole-5-carboxamide 5-amino-1-(β-D-ribofuranosyl)-4-(imidazol-2-yl)pyrazole 4-iodo-1-β-D-ribofuranosylpyrazole-3-carboxamide